trial

The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease

NCTId NCT06304233
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Active Not Recruiting
Enrollment 120 (estimated)
Sponsored by Norwegian University of Science and Technology
Primary completion 2026-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Active Not Recruiting
Enrollment
120 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2023-12-13
Primary completion
2026-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
EchocardiographyCardiac Magnetic Resonance ImagingElectrocardiographyBlood sampling

Sponsors

Norwegian University of Science and TechnologyLead Sponsor
St. Olavs HospitalCollaborator

Investigators

1
Morten A Høydal, PhDStudy Director

Sites

2 total
Trondheim, NorwayTrondheim, Norway

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2026-12
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Echocardiography
drug
Cardiac Magnetic Resonance Imaging
drug
Electrocardiography
drug
Blood sampling
drug
lead_sponsor
Norwegian University of Science and Technology
company
collaborator
St. Olavs Hospital
company
indication
Heart Diseases
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Morten A Høydal, PhD
person